Vertex Pharmaceuticals Stock Forecast, Price & News

$191.94
+4.42 (+2.36 %)
(As of 06/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$188.29
$193.28
50-Day Range
$187.49
$220.16
52-Week Range
$185.32
$306.08
Volume2.47 million shs
Average Volume2.05 million shs
Market Capitalization$49.69 billion
P/E Ratio18.28
Dividend YieldN/A
Beta0.68
30 days | 90 days | 365 days | Advanced Chart
Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Vertex Pharmaceuticals logo

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.35 out of 5 stars

Medical Sector

14th out of 2,105 stocks

Pharmaceutical Preparations Industry

6th out of 832 stocks

Analyst Opinion: 4.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

Is Vertex Pharmaceuticals a buy right now?

25 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Vertex Pharmaceuticals?

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Vertex Pharmaceuticals
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its earnings results on Thursday, April, 29th. The pharmaceutical company reported $2.98 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.60. The pharmaceutical company earned $1.72 billion during the quarter, compared to analyst estimates of $1.66 billion. Vertex Pharmaceuticals had a net margin of 43.06% and a trailing twelve-month return on equity of 29.61%.
View Vertex Pharmaceuticals' earnings history
.

How has Vertex Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRTX shares have decreased by 12.9% and is now trading at $191.94.
View which stocks have been most impacted by COVID-19
.

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals declared that its board has approved a stock repurchase plan on Wednesday, July 31st 2019, which authorizes the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $6.70 billion-$6.90 billion, compared to the consensus revenue estimate of $6.95 billion.

What price target have analysts set for VRTX?

25 brokers have issued 1-year price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $200.00 to $340.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $275.86 in the next year. This suggests a possible upside of 43.7% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Dr. Jeffrey Marc Leiden, Exec. Chairman (Age 65, Pay $3.14M)
  • Dr. Reshma Kewalramani, CEO, Pres & Director (Age 48, Pay $3.86M)
  • Mr. Charles F. Wagner Jr., Exec. VP & CFO (Age 53, Pay $1.71M)
  • Mr. Stuart A. Arbuckle, EVP, Chief Commercial & Operations Officer (Age 55, Pay $2.03M)
  • Dr. David M. Altshuler, Exec. VP of Global Research & Chief Scientific Officer (Age 56, Pay $1.81M)
  • Ms. Kristen Ambrose, Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services (Age 45)
  • Mr. Mike Tirozzi, SVP and Chief Information & Data Officer
  • Mr. Michael Partridge, Sr. VP of Investor Relations
  • Mr. Damian W. Wilmot Esq., Sr. VP, Chief Risk and Compliance Officer (Age 45)
  • Ms. Joy Liu, Sr. VP & Gen. Counsel

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.37%), Price T Rowe Associates Inc. MD (6.39%), Alliancebernstein L.P. (3.04%), Capital International Investors (2.33%), Clearbridge Investments LLC (2.13%) and Janus Henderson Group PLC (1.74%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals
.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Putnam Investments LLC, Capital International Investors, Thrivent Financial for Lutherans, Fred Alger Management LLC, Assenagon Asset Management S.A., and Man Group plc. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, and Stuart A Arbuckle.
View insider buying and selling activity for Vertex Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Canada Pension Plan Investment Board, Ameriprise Financial Inc., ARK Investment Management LLC, Mayflower Financial Advisors LLC, Manning & Napier Group LLC, Point72 Asset Management L.P., and Armistice Capital LLC.
View insider buying and selling activity for Vertex Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $191.94.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals has a market capitalization of $49.69 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $9.03 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals employs 3,400 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Vertex Pharmaceuticals: Semma Therapeutics.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

Where are Vertex Pharmaceuticals' headquarters?

Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100 or via email at [email protected]


This page was last updated on 6/25/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.